カテゴリー： Market Monitor Global, 世界, 医療/バイオ

RdRp阻害剤&3CLプロテアーゼ阻害剤の世界市場見通し2023年-2029年

◆英語タイトル：RdRp Inhibitor and 3CL Protease Inhibitor Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2508）

◆商品コード：MMG23FB2508
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：118
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場規模と予測を収録しています。・世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：売上、2018年-2023年、2024年-2029年
・世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「RdRp阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

RdRp阻害剤&3CLプロテアーゼ阻害剤のグローバル主要企業は、Henan Zhenzhen Biotechnology Co., Ltd.、Shanghai Junshi biosciences Co., Ltd、Kexing Biopharm、Ascletis Pharma Inc.、China Resources Double Crane Pharmaceutical Company Limited、Todos Medical、Pfizer、Shionogi、Enanta Pharmaceuticals、Cocrystal Pharma、Insilico Medicine、Everest Medicines、Raynovent、Simcere、Cosunter、Frontier Biotechnologiesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、RdRp阻害剤&3CLプロテアーゼ阻害剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：タイプ別、2018年-2023年、2024年-2029年
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：タイプ別市場シェア、2022年
・RdRp阻害剤、3CLプロテアーゼ阻害剤

世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：用途別、2018年-2023年、2024年-2029年
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：用途別市場シェア、2022年
・病院、診療所、その他

世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：地域・国別、2018年-2023年、2024年-2029年
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるRdRp阻害剤&3CLプロテアーゼ阻害剤のグローバル売上、2018年-2023年
・主要企業におけるRdRp阻害剤&3CLプロテアーゼ阻害剤のグローバル売上シェア、2022年
・主要企業におけるRdRp阻害剤&3CLプロテアーゼ阻害剤のグローバル販売量、2018年-2023年
・主要企業におけるRdRp阻害剤&3CLプロテアーゼ阻害剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Henan Zhenzhen Biotechnology Co., Ltd.、Shanghai Junshi biosciences Co., Ltd、Kexing Biopharm、Ascletis Pharma Inc.、China Resources Double Crane Pharmaceutical Company Limited、Todos Medical、Pfizer、Shionogi、Enanta Pharmaceuticals、Cocrystal Pharma、Insilico Medicine、Everest Medicines、Raynovent、Simcere、Cosunter、Frontier Biotechnologies

*************************************************************

・調査・分析レポートの概要
RdRp阻害剤&3CLプロテアーゼ阻害剤市場の定義
市場セグメント
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場規模
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場規模：2022年 VS 2029年
世界のRdRp阻害剤&3CLプロテアーゼ阻害剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのRdRp阻害剤&3CLプロテアーゼ阻害剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のRdRp阻害剤&3CLプロテアーゼ阻害剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：RdRp阻害剤、3CLプロテアーゼ阻害剤
RdRp阻害剤&3CLプロテアーゼ阻害剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
RdRp阻害剤&3CLプロテアーゼ阻害剤の用途別グローバル売上・予測

・地域別市場分析
地域別RdRp阻害剤&3CLプロテアーゼ阻害剤市場規模 2022年と2029年
地域別RdRp阻害剤&3CLプロテアーゼ阻害剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Henan Zhenzhen Biotechnology Co., Ltd.、Shanghai Junshi biosciences Co., Ltd、Kexing Biopharm、Ascletis Pharma Inc.、China Resources Double Crane Pharmaceutical Company Limited、Todos Medical、Pfizer、Shionogi、Enanta Pharmaceuticals、Cocrystal Pharma、Insilico Medicine、Everest Medicines、Raynovent、Simcere、Cosunter、Frontier Biotechnologies
...

RdRp inhibitors can inhibit the activity of viral RdRp enzymes, terminate viral replication, and achieve antiviral effects. Drugs that inhibit the cleavage of polyproteins into functional proteins are called protease inhibitors. 3CL Protease Inhibitors are inhibitors of protein-based enzymes that normally inhibit the breakdown of polyproteins into functional proteins, thus preventing viral reproduction.
This report aims to provide a comprehensive presentation of the global market for RdRp Inhibitor and 3CL Protease Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RdRp Inhibitor and 3CL Protease Inhibitor. This report contains market size and forecasts of RdRp Inhibitor and 3CL Protease Inhibitor in global, including the following market information:
Global RdRp Inhibitor and 3CL Protease Inhibitor Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global RdRp Inhibitor and 3CL Protease Inhibitor Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five RdRp Inhibitor and 3CL Protease Inhibitor companies in 2022 (%)
The global RdRp Inhibitor and 3CL Protease Inhibitor market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
RdRp Inhibitor Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of RdRp Inhibitor and 3CL Protease Inhibitor include Henan Zhenzhen Biotechnology Co., Ltd., Shanghai Junshi biosciences Co., Ltd, Kexing Biopharm, Ascletis Pharma Inc., China Resources Double Crane Pharmaceutical Company Limited, Todos Medical, Pfizer, Shionogi and Enanta Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the RdRp Inhibitor and 3CL Protease Inhibitor manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global RdRp Inhibitor and 3CL Protease Inhibitor Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global RdRp Inhibitor and 3CL Protease Inhibitor Market Segment Percentages, by Type, 2022 (%)
RdRp Inhibitor
3CL Protease Inhibitor
Global RdRp Inhibitor and 3CL Protease Inhibitor Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global RdRp Inhibitor and 3CL Protease Inhibitor Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Other
Global RdRp Inhibitor and 3CL Protease Inhibitor Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global RdRp Inhibitor and 3CL Protease Inhibitor Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies RdRp Inhibitor and 3CL Protease Inhibitor revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies RdRp Inhibitor and 3CL Protease Inhibitor revenues share in global market, 2022 (%)
Key companies RdRp Inhibitor and 3CL Protease Inhibitor sales in global market, 2018-2023 (Estimated), (K Units)
Key companies RdRp Inhibitor and 3CL Protease Inhibitor sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Henan Zhenzhen Biotechnology Co., Ltd.
Shanghai Junshi biosciences Co., Ltd
Kexing Biopharm
Ascletis Pharma Inc.
China Resources Double Crane Pharmaceutical Company Limited
Todos Medical
Pfizer
Shionogi
Enanta Pharmaceuticals
Cocrystal Pharma
Insilico Medicine
Everest Medicines
Raynovent
Simcere
Cosunter
Frontier Biotechnologies
Outline of Major Chapters:
Chapter 1: Introduces the definition of RdRp Inhibitor and 3CL Protease Inhibitor, market overview.
Chapter 2: Global RdRp Inhibitor and 3CL Protease Inhibitor market size in revenue and volume.
Chapter 3: Detailed analysis of RdRp Inhibitor and 3CL Protease Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of RdRp Inhibitor and 3CL Protease Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global RdRp Inhibitor and 3CL Protease Inhibitor capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 RdRp Inhibitor and 3CL Protease Inhibitor Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global RdRp Inhibitor and 3CL Protease Inhibitor Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global RdRp Inhibitor and 3CL Protease Inhibitor Overall Market Size
2.1 Global RdRp Inhibitor and 3CL Protease Inhibitor Market Size: 2022 VS 2029
2.2 Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, Prospects & Forecasts: 2018-2029
2.3 Global RdRp Inhibitor and 3CL Protease Inhibitor Sales: 2018-2029
3 Company Landscape
3.1 Top RdRp Inhibitor and 3CL Protease Inhibitor Players in Global Market
3.2 Top Global RdRp Inhibitor and 3CL Protease Inhibitor Companies Ranked by Revenue
3.3 Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue by Companies
3.4 Global RdRp Inhibitor and 3CL Protease Inhibitor Sales by Companies
3.5 Global RdRp Inhibitor and 3CL Protease Inhibitor Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 RdRp Inhibitor and 3CL Protease Inhibitor Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers RdRp Inhibitor and 3CL Protease Inhibitor Product Type
3.8 Tier 1, Tier 2 and Tier 3 RdRp Inhibitor and 3CL Protease Inhibitor Players in Global Market
3.8.1 List of Global Tier 1 RdRp Inhibitor and 3CL Protease Inhibitor Companies
3.8.2 List of Global Tier 2 and Tier 3 RdRp Inhibitor and 3CL Protease Inhibitor Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Market Size Markets, 2022 & 2029
4.1.2 RdRp Inhibitor
4.1.3 3CL Protease Inhibitor
4.2 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue & Forecasts
4.2.1 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2023
4.2.2 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2024-2029
4.2.3 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue Market Share, 2018-2029
4.3 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales & Forecasts
4.3.1 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2023
4.3.2 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2024-2029
4.3.3 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales Market Share, 2018-2029
4.4 By Type – Global RdRp Inhibitor and 3CL Protease Inhibitor Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue & Forecasts
5.2.1 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2023
5.2.2 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2024-2029
5.2.3 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue Market Share, 2018-2029
5.3 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales & Forecasts
5.3.1 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2023
5.3.2 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2024-2029
5.3.3 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales Market Share, 2018-2029
5.4 By Application – Global RdRp Inhibitor and 3CL Protease Inhibitor Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2022 & 2029
6.2 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue & Forecasts
6.2.1 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2023
6.2.2 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2024-2029
6.2.3 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Revenue Market Share, 2018-2029
6.3 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales & Forecasts
6.3.1 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2023
6.3.2 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2024-2029
6.3.3 By Region – Global RdRp Inhibitor and 3CL Protease Inhibitor Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2029
6.4.2 By Country – North America RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2029
6.4.3 US RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.4.4 Canada RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.4.5 Mexico RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2029
6.5.2 By Country – Europe RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2029
6.5.3 Germany RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.4 France RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.5 U.K. RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.6 Italy RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.7 Russia RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.8 Nordic Countries RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.5.9 Benelux RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2029
6.6.2 By Region – Asia RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2029
6.6.3 China RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.6.4 Japan RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.6.5 South Korea RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.6.6 Southeast Asia RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.6.7 India RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2029
6.7.2 By Country – South America RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2029
6.7.3 Brazil RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.7.4 Argentina RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa RdRp Inhibitor and 3CL Protease Inhibitor Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa RdRp Inhibitor and 3CL Protease Inhibitor Sales, 2018-2029
6.8.3 Turkey RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.8.4 Israel RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.8.5 Saudi Arabia RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
6.8.6 UAE RdRp Inhibitor and 3CL Protease Inhibitor Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Henan Zhenzhen Biotechnology Co., Ltd.
7.1.1 Henan Zhenzhen Biotechnology Co., Ltd. Company Summary
7.1.2 Henan Zhenzhen Biotechnology Co., Ltd. Business Overview
7.1.3 Henan Zhenzhen Biotechnology Co., Ltd. RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.1.4 Henan Zhenzhen Biotechnology Co., Ltd. RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.1.5 Henan Zhenzhen Biotechnology Co., Ltd. Key News & Latest Developments
7.2 Shanghai Junshi biosciences Co., Ltd
7.2.1 Shanghai Junshi biosciences Co., Ltd Company Summary
7.2.2 Shanghai Junshi biosciences Co., Ltd Business Overview
7.2.3 Shanghai Junshi biosciences Co., Ltd RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.2.4 Shanghai Junshi biosciences Co., Ltd RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.2.5 Shanghai Junshi biosciences Co., Ltd Key News & Latest Developments
7.3 Kexing Biopharm
7.3.1 Kexing Biopharm Company Summary
7.3.2 Kexing Biopharm Business Overview
7.3.3 Kexing Biopharm RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.3.4 Kexing Biopharm RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.3.5 Kexing Biopharm Key News & Latest Developments
7.4 Ascletis Pharma Inc.
7.4.1 Ascletis Pharma Inc. Company Summary
7.4.2 Ascletis Pharma Inc. Business Overview
7.4.3 Ascletis Pharma Inc. RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.4.4 Ascletis Pharma Inc. RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.4.5 Ascletis Pharma Inc. Key News & Latest Developments
7.5 China Resources Double Crane Pharmaceutical Company Limited
7.5.1 China Resources Double Crane Pharmaceutical Company Limited Company Summary
7.5.2 China Resources Double Crane Pharmaceutical Company Limited Business Overview
7.5.3 China Resources Double Crane Pharmaceutical Company Limited RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.5.4 China Resources Double Crane Pharmaceutical Company Limited RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.5.5 China Resources Double Crane Pharmaceutical Company Limited Key News & Latest Developments
7.6 Todos Medical
7.6.1 Todos Medical Company Summary
7.6.2 Todos Medical Business Overview
7.6.3 Todos Medical RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.6.4 Todos Medical RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.6.5 Todos Medical Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.7.4 Pfizer RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer Key News & Latest Developments
7.8 Shionogi
7.8.1 Shionogi Company Summary
7.8.2 Shionogi Business Overview
7.8.3 Shionogi RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.8.4 Shionogi RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.8.5 Shionogi Key News & Latest Developments
7.9 Enanta Pharmaceuticals
7.9.1 Enanta Pharmaceuticals Company Summary
7.9.2 Enanta Pharmaceuticals Business Overview
7.9.3 Enanta Pharmaceuticals RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.9.4 Enanta Pharmaceuticals RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.9.5 Enanta Pharmaceuticals Key News & Latest Developments
7.10 Cocrystal Pharma
7.10.1 Cocrystal Pharma Company Summary
7.10.2 Cocrystal Pharma Business Overview
7.10.3 Cocrystal Pharma RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.10.4 Cocrystal Pharma RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.10.5 Cocrystal Pharma Key News & Latest Developments
7.11 Insilico Medicine
7.11.1 Insilico Medicine Company Summary
7.11.2 Insilico Medicine RdRp Inhibitor and 3CL Protease Inhibitor Business Overview
7.11.3 Insilico Medicine RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.11.4 Insilico Medicine RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.11.5 Insilico Medicine Key News & Latest Developments
7.12 Everest Medicines
7.12.1 Everest Medicines Company Summary
7.12.2 Everest Medicines RdRp Inhibitor and 3CL Protease Inhibitor Business Overview
7.12.3 Everest Medicines RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.12.4 Everest Medicines RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.12.5 Everest Medicines Key News & Latest Developments
7.13 Raynovent
7.13.1 Raynovent Company Summary
7.13.2 Raynovent RdRp Inhibitor and 3CL Protease Inhibitor Business Overview
7.13.3 Raynovent RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.13.4 Raynovent RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.13.5 Raynovent Key News & Latest Developments
7.14 Simcere
7.14.1 Simcere Company Summary
7.14.2 Simcere Business Overview
7.14.3 Simcere RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.14.4 Simcere RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.14.5 Simcere Key News & Latest Developments
7.15 Cosunter
7.15.1 Cosunter Company Summary
7.15.2 Cosunter Business Overview
7.15.3 Cosunter RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.15.4 Cosunter RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.15.5 Cosunter Key News & Latest Developments
7.16 Frontier Biotechnologies
7.16.1 Frontier Biotechnologies Company Summary
7.16.2 Frontier Biotechnologies Business Overview
7.16.3 Frontier Biotechnologies RdRp Inhibitor and 3CL Protease Inhibitor Major Product Offerings
7.16.4 Frontier Biotechnologies RdRp Inhibitor and 3CL Protease Inhibitor Sales and Revenue in Global (2018-2023)
7.16.5 Frontier Biotechnologies Key News & Latest Developments
8 Global RdRp Inhibitor and 3CL Protease Inhibitor Production Capacity, Analysis
8.1 Global RdRp Inhibitor and 3CL Protease Inhibitor Production Capacity, 2018-2029
8.2 RdRp Inhibitor and 3CL Protease Inhibitor Production Capacity of Key Manufacturers in Global Market
8.3 Global RdRp Inhibitor and 3CL Protease Inhibitor Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 RdRp Inhibitor and 3CL Protease Inhibitor Supply Chain Analysis
10.1 RdRp Inhibitor and 3CL Protease Inhibitor Industry Value Chain
10.2 RdRp Inhibitor and 3CL Protease Inhibitor Upstream Market
10.3 RdRp Inhibitor and 3CL Protease Inhibitor Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 RdRp Inhibitor and 3CL Protease Inhibitor Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ RdRp阻害剤&3CLプロテアーゼ阻害剤の世界市場見通し2023年-2029年(RdRp Inhibitor and 3CL Protease Inhibitor Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

RdRp阻害剤&3CLプロテアーゼ阻害剤の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp